Search
tremelimumab (Imjudo)
Indications:
- experimental agent for metastatic melanoma
- metastatic head & neck cancer PD-L1 negative [2]
- in combination with durvalumab for treatment of hepatocellular carcinoma [3]
Dosage:
- once a month dosing (phase 2 trials)
- 15 mg/kg every 3 months selected for further clinical testing
- monotherapy or in combination with durvalumab
- alone at 10 mg/kg intravenously every 4 weeks for 7 cycles then every 12 weeks for 2 cycles [2]
Adverse effects:
- diarrhea, rash, pruritus
Mechanism of action:
- human IgG2 monoclonal antibody
- blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA4)
- promotes T-cell activity
- does not deplete regulatory T cells [2]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Camacho LH et al.
Phase I/II trial of tremelimumab in patients with metastatic
melanoma.
J Clin Oncol 2009 Mar 1; 27:1075.
PMID: 19139427
- Fuerst ML with comments by Klil-Drori AJ
Durvalumab Combo Slows PD-L1-neg Advanced Head and Neck Cancer.
Increase in 'clinically relevant' overall survival, with
manageable toxicity
MedPage Today. ASCO Reading Room 05.03.2018
https://www.medpagetoday.com/reading-room/asco/immunotherapy/72666
- Siu L, et al
A randomized, open-label, multicenter, global phase 2 study
of durvalumab (D), tremelimumab (T), or D plus T in patients
with PD-L1 low/negative recurrent or metastatic (R/M) head
and neck squamous cell carcinoma (HNSCC): CONDOR
Int J Rad Oncol Biol Physics 2018; 100 (5): 1307.
Not indexed in PubMed
- Leiser M
FDA approves tremelimumab with durvalumab for advanced liver cancer.
Helio. Oct 24, 2022
https://www.healio.com/news/hematology-oncology/20221024/fda-approves-tremelimumab-with-durvalumab-for-advanced-liver-cancer